FDA clears more saline imports to address shortage

Federal health regulators are allowing a U.S. medical supply company to import saline solution from its Spanish plant to address a national shortage of the hospital staple.

The Food and Drug Administration announcement is the latest effort to increase U.S. supplies of the salt solution, which is used to rehydrate hospital patients and assist in the delivery of drugs.

The agency said late Monday that it cleared Baxter Healthcare to import from its facility in Spain after FDA inspectors verified that it meets U.S. standards. Last month the FDA cleared another company, Fresenius Kabi, to import saline from its Norway plant.

The FDA began receiving reports of a supply problem from hospitals in December due to production delays, maintenance problems and other issues.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA takes action to ease neonatal drug shortage

May 29, 2013

(AP)—Federal health regulators will allow overseas imports of a critical intravenous drug formula used to nourish premature infants, amid a shortage that has impacted hospitals nationwide.

US halts drug imports from Ranbaxy plant in India

Jan 23, 2014

U.S. health regulators said Thursday they are barring imported drugs from an overseas factory operated by Ranbaxy Laboratories, India's largest drugmaker, due to quality control violations.

Nitroglycerin shortage has medical community worried

Mar 27, 2014

(HealthDay)—An ongoing shortage of the drug nitroglycerin is causing problems and concerns for doctors and hospitals in the United States. The drug is often the first therapy used by emergency room doctors ...

Recommended for you

Powdered measles vaccine found safe in early clinical trials

11 hours ago

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

Health care M&A leads global deal surge

Nov 23, 2014

In a big year for deal making, the health care industry is a standout. Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.